Silence Therapeutics plc (SLNCF)
USD 0.97
(21.25%)
USD 0.97
(21.25%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -49.77 Million GBP | 0.47% |
| 2022 | -47.88 Million GBP | -5.53% |
| 2021 | -45.42 Million GBP | -28.83% |
| 2020 | -35.52 Million GBP | -58.48% |
| 2019 | -22.35 Million GBP | -10.39% |
| 2018 | -20.13 Million GBP | 12.56% |
| 2017 | -3.32 Million GBP | -98.55% |
| 2016 | -11.59 Million GBP | -20.96% |
| 2015 | -9.58 Million GBP | 18.72% |
| 2014 | -11.79 Million GBP | -34.42% |
| 2013 | -8.77 Million GBP | -79.89% |
| 2012 | -5.3 Million GBP | 2.67% |
| 2011 | -5.41 Million GBP | 38.65% |
| 2010 | -8.17 Million GBP | -59.48% |
| 2009 | -6.15 Million GBP | 31.15% |
| 2008 | -7.44 Million GBP | -44.15% |
| 2007 | -5.31 Million GBP | -44.03% |
| 2006 | -3.58 Million GBP | -5.1% |
| 2005 | -3.41 Million GBP | -6.66% |
| 2004 | -3.19 Million GBP | -21.61% |
| 2003 | -2.62 Million GBP | -34.89% |
| 2002 | -1.94 Million GBP | 34.71% |
| 2001 | -2.98 Million GBP | -10.31% |
| 2000 | -2.7 Million GBP | -24.53% |
| 1999 | -2.17 Million GBP | -16.39% |
| 1998 | -1.86 Million GBP | 12.14% |
| 1997 | -2.12 Million GBP | -75.62% |
| 1996 | -1.21 Million GBP | -29.83% |
| 1995 | -932 Thousand GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -17.13 Million GBP | -324.65% |
| 2024 Q1 | -3.23 Million GBP | 69.46% |
| 2023 FY | - GBP | 0.47% |
| 2023 Q2 | -10.99 Million GBP | 5.82% |
| 2023 Q4 | -14.9 Million GBP | -41.6% |
| 2023 Q1 | -11.67 Million GBP | 21.6% |
| 2023 Q3 | -10.52 Million GBP | 4.28% |
| 2022 FY | - GBP | -5.53% |
| 2022 Q2 | -13.3 Million GBP | -40.67% |
| 2022 Q3 | -9.17 Million GBP | 31.02% |
| 2022 Q1 | -9.45 Million GBP | 15.84% |
| 2022 Q4 | -14.89 Million GBP | -62.3% |
| 2021 Q2 | -12.58 Million GBP | -36.63% |
| 2021 FY | - GBP | -28.83% |
| 2021 Q1 | -9.21 Million GBP | 29.63% |
| 2021 Q3 | -11.87 Million GBP | 5.62% |
| 2021 Q4 | -11.23 Million GBP | 5.38% |
| 2020 Q2 | -6.98 Million GBP | 0.0% |
| 2020 FY | - GBP | -58.48% |
| 2020 Q1 | -6.98 Million GBP | -10.03% |
| 2020 Q3 | -9.32 Million GBP | -33.41% |
| 2020 Q4 | -13.08 Million GBP | -40.36% |
| 2019 Q1 | -4.72 Million GBP | 9.75% |
| 2019 FY | - GBP | -10.39% |
| 2019 Q2 | -4.72 Million GBP | 0.0% |
| 2019 Q3 | -6.44 Million GBP | -36.46% |
| 2019 Q4 | -6.35 Million GBP | 1.49% |
| 2018 Q1 | -4.85 Million GBP | -32.26% |
| 2018 Q3 | -5.23 Million GBP | -7.96% |
| 2018 Q2 | -4.85 Million GBP | 0.0% |
| 2018 FY | - GBP | 12.56% |
| 2018 Q4 | -5.23 Million GBP | 0.0% |
| 2017 Q3 | -3.66 Million GBP | -10.72% |
| 2017 Q1 | -3.31 Million GBP | -31.98% |
| 2017 Q2 | -3.31 Million GBP | 0.0% |
| 2017 Q4 | -3.66 Million GBP | 0.0% |
| 2017 FY | - GBP | -98.55% |
| 2016 Q3 | -2.5 Million GBP | 23.69% |
| 2016 FY | - GBP | -20.96% |
| 2016 Q1 | -3.28 Million GBP | -30.03% |
| 2016 Q2 | -3.28 Million GBP | 0.0% |
| 2016 Q4 | -2.5 Million GBP | 0.0% |
| 2015 Q1 | -2.26 Million GBP | 26.89% |
| 2015 Q2 | -2.26 Million GBP | 0.0% |
| 2015 Q4 | -2.52 Million GBP | 0.0% |
| 2015 Q3 | -2.52 Million GBP | -11.68% |
| 2015 FY | - GBP | 18.72% |
| 2014 FY | - GBP | -34.42% |
| 2014 Q4 | -3.09 Million GBP | 0.0% |
| 2014 Q3 | -3.09 Million GBP | -10.63% |
| 2014 Q2 | -2.8 Million GBP | 0.0% |
| 2014 Q1 | -2.8 Million GBP | -1.76% |
| 2013 FY | - GBP | -79.89% |
| 2013 Q4 | -2.75 Million GBP | 0.0% |
| 2013 Q1 | -1.63 Million GBP | 0.0% |
| 2013 Q2 | -1.63 Million GBP | 0.0% |
| 2013 Q3 | -2.75 Million GBP | -68.18% |
| 2012 Q2 | - GBP | 0.0% |
| 2012 FY | - GBP | 2.67% |
| 2011 FY | - GBP | 38.65% |
| 2011 Q2 | - GBP | 0.0% |
| 2010 Q2 | - GBP | 0.0% |
| 2010 FY | - GBP | -59.48% |
| 2009 FY | - GBP | 31.15% |
| 2009 Q2 | - GBP | 0.0% |
| 2008 Q2 | - GBP | 0.0% |
| 2008 FY | - GBP | -44.15% |
| 2007 FY | - GBP | -44.03% |
| 2007 Q2 | - GBP | 0.0% |
| 2006 FY | - GBP | -5.1% |
| 2006 Q2 | - GBP | 0.0% |
| 2005 FY | - GBP | -6.66% |
| 2005 Q2 | - GBP | 0.0% |
| 2004 Q2 | - GBP | 0.0% |
| 2004 FY | - GBP | -21.61% |
| 2003 FY | - GBP | -34.89% |
| 2003 Q2 | - GBP | 0.0% |
| 2002 FY | - GBP | 34.71% |
| 2001 FY | - GBP | -10.31% |
| 2000 FY | - GBP | -24.53% |
| 1999 FY | - GBP | -16.39% |
| 1998 FY | - GBP | 12.14% |
| 1997 FY | - GBP | -75.62% |
| 1996 FY | - GBP | -29.83% |
| 1995 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ContraFect Corporation | -64.99 Million USD | 23.417% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 29.926% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -739.581% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -20714.552% |
| SQZ Biotechnologies Company | -64.14 Million USD | 22.393% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -1782.359% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -186.575% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 152.934% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -3140.652% |
| Marizyme, Inc. | -34.28 Million USD | -45.204% |
| Genus plc | 73.7 Million USD | 167.541% |
| Pharming Group N.V. | 9.87 Million USD | 603.979% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -3246.618% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -1303.384% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -467.465% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -3450.986% |
| IMV Inc. | -35.52 Million USD | -40.127% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -2042.076% |
| ONE Bio Corp. | 13.61 Million USD | 465.664% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -3.216% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -7771.209% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -2078.956% |
| Biomind Labs Inc. | -1.03 Million USD | -4711.565% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -25.585% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -595.1% |
| Skye Bioscience, Inc. | -13.54 Million USD | -267.432% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 740403.391% |
| Mesoblast Limited | -62.38 Million USD | 20.214% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -199012.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -1181.511% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -213.666% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -1889.559% |
| GB Sciences, Inc. | -1.41 Million USD | -3405.777% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -9508.799% |
| Alpha Cognition Inc. | -9.7 Million USD | -412.879% |
| HST Global, Inc. | -5303.00 USD | -938576.221% |
| CSL Limited | 4.78 Billion USD | 101.039% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Agentix Corp. | -1.37 Million USD | -3528.779% |
| Halberd Corporation | -74.27 Thousand USD | -66914.903% |
| Enzolytics Inc. | -2.12 Million USD | -2245.774% |
| Resverlogix Corp. | -11.74 Million USD | -323.931% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -1525.13% |
| argenx SE | -216.02 Million USD | 76.957% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 4190.222% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 1493.561% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 13239.445% |
| Bioxytran, Inc. | -3.82 Million USD | -1203.039% |
| Zenith Capital Corp. | -8.6 Million USD | -478.41% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -1934.694% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -28179.04% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -2491.375% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Genscript Biotech Corporation | -248.71 Million USD | 79.986% |
| Kadimastem Ltd | -2.62 Million USD | -1796.752% |
| Helix BioMedix, Inc. | -1.04 Million USD | -4657.472% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -1621.037% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -2744.459% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -652.898% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -999.776% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -1228.682% |
| EV Biologics, Inc. | -1.26 Million USD | -3828.399% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -27388.293% |
| Q BioMed Inc. | -617.62 Thousand USD | -7959.544% |
| LadRx Corporation | 412.28 Thousand USD | 12173.745% |
| Cell Source, Inc. | -4.27 Million USD | -1065.072% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -13455.325% |
| Regen BioPharma, Inc. | 1.46 Million USD | 3495.6% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 10.049% |
| Itoco Inc. | -1.86 Million USD | -2563.357% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -13012.586% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -2319.932% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 662.222% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -4360.394% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -3220.955% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.11 Million USD | -714.345% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -285635.606% |
| NovAccess Global Inc. | -1.03 Million USD | -4710.412% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -62887.005% |
| BioStem Technologies, Inc. | -7.55 Million USD | -558.993% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -406948.818% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Qrons Inc. | -40.08 Thousand USD | -124093.508% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -10149.177% |
| SYBLEU INC | -141.57 Thousand USD | -35061.156% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 9537.786% |
| Rebus Holdings, Inc. | -951 Thousand USD | -5134.28% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -5212.776% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -4587.15% |
| Affymax, Inc. | -14.29 Million USD | -248.22% |
| Mobile Lads Corp. | -2.24 Million USD | -2121.083% |
| International Stem Cell Corporation | 202 Thousand USD | 24742.574% |
| CytoDyn Inc. | -18.02 Million USD | -176.1% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -94463.07% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -1921.908% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -38.777% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -110517.778% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -1718.042% |
| Neutra Corp. | -181.24 Thousand USD | -27364.179% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -146.927% |
| PureTech Health plc | -11.62 Million USD | -328.124% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -146.944% |
| IXICO plc | -707 Thousand USD | -6940.736% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -547.729% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -2.962% |
| CSL Limited | 4.73 Billion USD | 101.052% |
| Cellectis S.A. | -92.63 Million USD | 46.265% |